Cross-cultural Validation of a Screening Scale for the Misuse of Opioid Analgesics in Primary Care
CompletedNCT05431985
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Objective: Analgesic Opioids misuse among patients with chronic pain ranges from 0% to 50%. The general practitioner is the first prescriber of opioid analgesics Our objective was to validate in primary care the POMI (Prescription Opioid Misuse Index) to identify the misuse of AOs. Study Setting: Patients with chronic pain, taking AOs for at least 3 months, and followed in general practice. Study design: Psychometric study Data Collection/Extraction methods: Eligible patients followed in general practice responded to the POMI: Test phase. They then responded after 2 weeks: the retest. The gold standard used was the DSM-V.
Study details
- Official title
- Cross-cultural Validation of a Screening Scale for the Misuse of Opioid Analgesics in Primary Care
- Conditions
- Chronic Pain
- Addiction Opiate
- Sponsor
- University Hospital, Clermont-Ferrand
- Start date
- 2017-01-01
- Primary completion
- 2019-03-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 5
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients aged 18 and over, * Patients with chronic pain for at least 6 months, * Patients with a prescription from the GP of at least one Opioid analgesic drug taken daily for at least the previous 3 months, * Patients registered with the French insurance system. Exclusion Criteria: * Discontinuation of opioid prescriptions on the test phase day (no Retest possible), * Patients in the process of withdrawal (risk of having been withdrawn during the Retest phase), * Patients unable to complete the questionnaire alone, * Patients who are monitored by a pain clinic or addiction centre, * Patients with ongoing cancer, * Patients refusing to participate.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05431985